Treatment resistant depression: Assessing the use of second-line therapies
10/16/2012 12:00 PM - 1:00 PM
Graduate Student Seminar
Amany Hassan, Department of Social and Administrative Sciences, OU College of Pharmacy
CPB 101 (OKC) and 1D29 (Tulsa)
Many patients treated for major depressive disorder (MDD) do not respond to initial first-line therapies. A lack of treatment success combined with a frequent need to augment initial treatment can consume a significant amount of additional healthcare resources. Different types of second-line agents can be used to treat patients classified as resistant to treatment. These include: a) augmenting antidepressants with lithium, triiodothyronine, or buspirone; b) using an atypical antipsychotic as adjunctive therapy; and c) combining or switching antidepressants. This study uses the Oklahoma Medicaid paid claims data to decribe the prescribing patterns of second-line agents among depressed patients, access if patients are receiving an adequate trial of first-line antidepressant before adding new medications, identify the factors that predict the type of second-line treatment, and evaluate the impact of each of these treatment strategies on the health care utilization and costs.